Zevra Therapeutics (ZVRA) Common Equity (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of Common Equity data on file, last reported at $6000.0 in Q1 2026.

• Quarterly Common Equity fell 99.99% year-over-year to $6000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6000.0 (down 99.99% YoY) and the FY2025 annual result came in at $6000.0, down 99.98% from the prior year.
• Common Equity was little changed at $6000.0 in Q1 2026, from $6000.0 in the prior quarter.
• In the past five years, Common Equity ranged from a high of $117.2 million in Q2 2025 to a low of -$16.7 million in Q3 2022.
• A 5-year average of $40.1 million and a median of $44.9 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity plunged 112.7% — and 2023, when it soared 886.45%.
• Tracing ZVRA's Common Equity over 5 years: stood at $75.1 million in 2022, then declined by 17.65% to $61.9 million in 2023, then slumped by 35.88% to $39.7 million in 2024, then sank by 99.98% to $6000.0 in 2025, then changed by 0.0% to $6000.0 in 2026.
• The last three Common Equity figures came in at $6000.0 (Q1 2026), $6000.0 (Q4 2025), and $6000.0 (Q3 2025), per Business Quant data.